| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/10/2005 | US20050032801 Compositions containing a ruthenium(III) complex and a heterocycle |
| 02/10/2005 | US20050032799 Treating a CNS disorder by orally administering to a patient a therapeutically effective amount of lamotrigine or a pharmaceutically acceptable derivative; for treatment of epilepsy, pain, edema, multiple sclerosis, psychological disorders, schizophrenia, bipolar disorders; side effect reduction |
| 02/10/2005 | US20050032762 injectable formulations comprising mixtures of testosterone ester such as testosterone undecanoate, in vehicles comprising castor oils and cosolvents; hormone replacement therapy and male contraception |
| 02/10/2005 | US20050032749 Pamidronate solution |
| 02/10/2005 | US20050032742 Chemo-enzymatic synthesis of sialylated oligosaccharides |
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032698 includes a divalent cation (zinc chloride) in an amount effective to stabilize the hormone; osteoporosis |
| 02/10/2005 | US20050032688 Use of angiotensin II fragments and analogs thereof in tissue repair |
| 02/10/2005 | US20050032680 Method of treatment of vulval vestibulitis |
| 02/10/2005 | US20050032676 Administering lipidated glycopeptide antibiotic and cyclodextrin, reduced tissue accumulation of the glycopeptide antibiotic, reduced nephrotoxicity and reduced histamine release |
| 02/10/2005 | US20050032044 Lipid and cryoprotectant; gene therapy |
| 02/10/2005 | US20050032039 HIV-specific T-cell induction |
| 02/10/2005 | US20050031853 Pullulan film compositions |
| 02/10/2005 | US20050031772 Ginger extract preparation |
| 02/10/2005 | US20050031762 Mixture containing antioxidant; in vitro fermentated beans; mixing cocoa beans with acetic acid |
| 02/10/2005 | US20050031706 A bismuth containing agent , a non-clay-derived suspending agent; an stabilizer for reducing viscosity change during storage of the formulation and water |
| 02/10/2005 | US20050031698 Hydroxyapatite/collagen (HAp/Col) nanocomposite; a bioabsorbable capsule capable of enclosing growth factor, DNA enzyme therein |
| 02/10/2005 | US20050031695 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| 02/10/2005 | US20050031693 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| 02/10/2005 | US20050031687 Enteric-coated proliposomal formulations for poorly water soluble drugs |
| 02/10/2005 | US20050031682 Modified calcium phosphate excipient |
| 02/10/2005 | US20050031680 In vivo use of water absorbent polymers |
| 02/10/2005 | US20050031677 Sequential drug delivery systems |
| 02/10/2005 | US20050031675 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/10/2005 | US20050031674 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 02/10/2005 | US20050031671 Weight management, longevity and health paradigm |
| 02/10/2005 | US20050031670 hunger-abating, low-calorie, and/or high energy edible composition comprising a bupropion compound and a food component |
| 02/10/2005 | US20050031666 implant comprising a chemonucleolysis agent in solid form, wherein the implant, when placed into the nucleus pulposus of an intervertebral disc, releases the chemonucleolysis agent into the nuclear disc tissue surrounding the implant to proteolytically degrade the tissue |
| 02/10/2005 | US20050031652 Compositions and methods comprising memantine and polyanionic polymers |
| 02/10/2005 | US20050031650 Composition with gelling properties for the sustained delivery of bioactive substances |
| 02/10/2005 | US20050031635 Inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic valency platform molecule and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen |
| 02/10/2005 | US20050031629 An immunogenic A beta fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the A beta fragment; Alzheimer's disease; antibodies |
| 02/10/2005 | US20050031627 Methods for preparing immunoconjugates |
| 02/10/2005 | US20050031626 Binding agents with differential activity |
| 02/10/2005 | US20050031625 First antibody binds CR1 receptor coupled to second antibody that binds to protective antigen component of anthrax toxin, but does not inhibit the binding of the protective antigen component of the anthrax toxin to cells |
| 02/10/2005 | US20050031589 Method of treating hepatitis C infection |
| 02/10/2005 | US20050031580 Emulsifier for highly liquid W/O emulsion based on partly crosslinked polyglycerol esters of polyhydroxystearic acid |
| 02/10/2005 | US20050031579 Polymer encapsulation of adenoviruses |
| 02/10/2005 | US20050031577 Therapeutic polyesters and polyamides |
| 02/10/2005 | US20050031576 Water-soluble polymer segment and a functional group such as a ketone, a ketone hydrate, a thione, wherein the functional group is part of a cyclic structure attached to polymer segment through either a direct covalent bond or through one or more atoms; useful for forming polymer-active agent conjugates |
| 02/10/2005 | US20050031575 Block copolymers |
| 02/10/2005 | US20050031548 Suspension aerosol formulations of pharmaceutical products |
| 02/10/2005 | DE10333443A1 Emulgator für dünnflüssige W/O-Emulsionen auf Basis von teilvernetzten Polyglycerinestern der Polyhydroxystearinsäure Emulsifier for highly liquid W / O emulsions based on partly crosslinked polyglycerol esters of polyhydroxystearic |
| 02/10/2005 | DE10297513T5 In vitro Herstellung von dendritischen Zellen aus CD14+ Monocyten In vitro production of dendritic cells from CD14 + monocytes |
| 02/10/2005 | DE10158447B4 Ascorbinsäure-Solubilisat Ascorbic acid-solubilized |
| 02/10/2005 | DE10059318B4 Kosmetische Mittel enthaltend Alk(en)ylbernsteinsäurederivate Cosmetic products containing ylbernsteinsäurederivate alk (en) |
| 02/10/2005 | CA2536120A1 Polymer encapsulation of adenoviruses |
| 02/10/2005 | CA2534360A1 Methods for expression and purification of immunotoxins |
| 02/10/2005 | CA2534042A1 Compositions for encapsulation and controlled release |
| 02/10/2005 | CA2533896A1 Improved stearate composition and method of production thereof |
| 02/10/2005 | CA2533639A1 Amino acid diamides in non alpha position useful as adjuvants for the administration of active biological agents |
| 02/10/2005 | CA2533128A1 Bioactive compositions comprising triazines |
| 02/10/2005 | CA2532931A1 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| 02/10/2005 | CA2532251A1 Cci-779 lyophilized formulations |
| 02/10/2005 | CA2530172A1 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/10/2005 | CA2526589A1 Processed fat composition for preventing/ameliorating lifestyle-related diseases |
| 02/09/2005 | EP1505089A1 Cationic (alkyl)acrylamide derivative, polymer based on these derivates, and transfection system comprising said polymer |
| 02/09/2005 | EP1505076A2 Specific antibody fragments for the human carcinoembryonic antigen (cea) |
| 02/09/2005 | EP1504766A1 Drug- or gene-carrier composition having lowered hemagglutinin activity |
| 02/09/2005 | EP1504765A1 Quickly soluble film preparations |
| 02/09/2005 | EP1504758A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/09/2005 | EP1504757A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/09/2005 | EP1504673A1 Hard sugar coated preparations, sugar coating solutions and process for producing hard sugar coated preparation |
| 02/09/2005 | EP1504108A2 Viral vector |
| 02/09/2005 | EP1504047A1 Polymeric microemulsions |
| 02/09/2005 | EP1504046A2 Tri-block polymers for nanosphere-based drug or gene delivery |
| 02/09/2005 | EP1504040A1 Method for reduction of residual organic solvent in carbomer |
| 02/09/2005 | EP1504010A1 Vitamin-mitomycin conjugates |
| 02/09/2005 | EP1503803A1 Medicinal formulation in particular for treating herniated invertebral discs |
| 02/09/2005 | EP1503802A2 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 02/09/2005 | EP1503801A2 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/09/2005 | EP1503800A1 Treatment and prevention of tissue damage |
| 02/09/2005 | EP1503799A2 Immunogenic, monoclonal antibody |
| 02/09/2005 | EP1503798A1 Stabilised solid compositions of modified factor vii |
| 02/09/2005 | EP1503797A1 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
| 02/09/2005 | EP1503793A2 Cancer vaccines and methods of using the same |
| 02/09/2005 | EP1503772A1 Soluble composition containing sporopollenin and the use thereof |
| 02/09/2005 | EP1503769A1 Antibiotic/benzoyl peroxide dispenser |
| 02/09/2005 | EP1503760A1 Camptothecin derivatives and polymeric conjugates thereof |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1503747A1 Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders |
| 02/09/2005 | EP1503741A2 Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
| 02/09/2005 | EP1503740A1 Monocompartment osmotic controlled drug delivery system |
| 02/09/2005 | EP1503739A1 Sustained release of guaifenesin combination drugs |
| 02/09/2005 | EP1503738A1 Use of completely linear short chain alpha-glucans as a pharmaceutical excipient |
| 02/09/2005 | EP1503737A1 Nanoparticulate nystatin formulations |
| 02/09/2005 | EP1503735A2 A direct cellular energy delivery system |
| 02/09/2005 | EP1503733A1 Oleaginous oral antiparasitic compositions |
| 02/09/2005 | EP1503732A2 Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation |
| 02/09/2005 | EP1503731A1 Processes for forming a drug delivery device |
| 02/09/2005 | EP1503730A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
| 02/09/2005 | EP1503722A2 Cosmetic product comprising at least one water-soluble copolymer which contains (meth)acrylamide units |
| 02/09/2005 | EP1503714A2 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/09/2005 | EP1453816A4 Phenoxy amine compounds and compositions for delivering active agents |
| 02/09/2005 | EP1432436A4 Nutrient therapy for immuno-compromised patients |
| 02/09/2005 | EP1420802A4 Increased solubility flavanolignan preparations |
| 02/09/2005 | EP1390031B1 Topical composition containing a fungicide |
| 02/09/2005 | EP1284601A4 Allantoin-containing skin cream |
| 02/09/2005 | EP1242121B1 Polypeptide compositions with improved stability |
| 02/09/2005 | EP1210119B1 Pharmaceutical compositions for oral and topical administration |